Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theralase Technologies Inc. TLTFF


Primary Symbol: V.TLT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > The overall pipeline
View:
Post by DJDawg on Nov 08, 2024 9:35pm

The overall pipeline

Thinking on the competition for BCG therapy I remain convinced that the key to longterm success is as follows.

- get BTD to show wider pool of investors that serious drug with good outcomes and FDA respect despite being a tiny tiny company on the tsx venture
- get a financial bump of some kind with the BTD
- use the money to widen the pipeline to show IV rutherrin could do amazing things for typically fatal GBM and advanced NSCLC
- get some kind of thing going with very interesting HSV data to further show the different pipelines

If they can show the world that not a one trick NMIBC pony then they will shoot up as the more viable avenues of sucess = more derisking compared to one drug and one narrow disease type of biotech company.
Comment by Yajne on Nov 08, 2024 10:32pm
Great post DJDawg...total agreement from me
Comment by CancerSlayer on Nov 08, 2024 11:51pm
Agree....would also really like to see the preclinical versatility of this drug begin to clinically shine.  If TLT can demonstrate that our versatile base compound can not only be applied to other indications systemically/intravenously, but also respond to a more simplified/external activation source (i.e. X-ray, other FDA approved compound, nano scintillation, etc.) in a highly unmet ...more  
Comment by DeathXray33 on Nov 10, 2024 2:24pm
I don't see Rutherrin ever becoming resistant like Cisplatin. Brilliant...
Comment by menoalittle on Nov 10, 2024 4:45pm
Probably because Rutherrin won't be in the same race that Cisplatin is in trying to knockout (or knockdown) carcinoma before it (the Cisplatin) kills you...
Comment by Johnandrose22 on Nov 10, 2024 6:50pm
A remarkable CR and jaw dropping durability...with often just one instillation...One!....Data confirmed by an FDA central lab....C'mon...just confirm this and start saving the lives of our family, neighbors and those we will never know.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities